Renal and vascular actions of urotensin II

被引:32
作者
Ashton, N. [1 ]
机构
[1] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England
关键词
kidney disease; water-electrolyte balance; glomerular filtration rate; Na transport; cardiovascular disease;
D O I
10.1038/sj.ki.5001621
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The peptide hormone urotensin II (UII) has been highly conserved through the vertebrates from fish to humans. As it was shown to be the endogenous ligand for the mammalian orphan G-protein-coupled receptor GPR14, now renamed the UT receptor, interest in UII physiology has grown. Initial observations of a potent vasoconstrictor effect have been tempered with the subsequent revelation of an endothelium-dependent vasodilator action. These complex and contrasting vascular actions are both species-and vascular bed-specific. UII also plays a role in body fluid regulation in lower vertebrates, and it now appears that this extends to mammals. The kidney is a major source of both circulating and urinary UII. UII is found in both the proximal tubules and collecting ducts; the UT receptor is localized primarily to the renal medulla, with greatest expression in the inner medullary collecting ducts. Infusion in rats produced conflicting results: exogenous UII has been shown to increase glomerular filtration rate (GFR) and excretion of water and sodium, but also to reduce the same variables. Inhibition of UT receptor activity with the antagonist urantide resulted in an increase in GFR, diuresis, and natriuresis, suggesting that endogenous UII exerts a tonic influence on basal renal function. UII may also play a role in renal disease, being elevated in the circulation or urine of patients with renal failure and in experimental models of cardiovascular disease such as the spontaneously hypertensive rat. It remains to be established whether these changes represent an underlying primary cause or a compensatory response.
引用
收藏
页码:624 / 629
页数:6
相关论文
共 33 条
  • [1] Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
    Ames, RS
    Sarau, HM
    Chambers, JK
    Willette, RN
    Alyar, NV
    Romanic, AM
    Louden, CS
    Foley, JJ
    Sauermelch, CF
    Coatney, RW
    Ao, ZH
    Disa, J
    Holmes, SD
    Stadel, JM
    Martin, JD
    Liu, WS
    Glover, GI
    Wilson, S
    McNulty, DE
    Ellis, CE
    Elshourbagy, NA
    Shabon, U
    Trill, JJ
    Hay, DWP
    Ohlstein, EH
    Bergsma, DJ
    Douglas, SA
    [J]. NATURE, 1999, 401 (6750) : 282 - 286
  • [2] Urotensin II: Ancient hormone with new functions in vertebrate body fluid regulation
    Balment, RJ
    Song, W
    Ashton, N
    [J]. TRENDS IN COMPARATIVE ENDOCRINOLOGY AND NEUROBIOLOGY, 2005, 1040 : 66 - 73
  • [3] Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water
    Bond, H
    Winter, MJ
    Warne, JM
    McCrohan, CR
    Balment, RJ
    [J]. GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2002, 125 (01) : 113 - 120
  • [4] Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors
    Camarda, V
    Song, W
    Marzola, E
    Spagnol, M
    Guerrini, R
    Salvadori, S
    Regoli, D
    Thompson, JP
    Rowbotham, DJ
    Behm, DJ
    Douglas, SA
    Calo, G
    Lambert, DG
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 498 (1-3) : 83 - 86
  • [5] Effects of human urotensin II in isolated vessels of various species;: comparison with other vasoactive agents
    Camarda, V
    Rizzi, A
    Calò, G
    Gendron, G
    Perron, SI
    Kostenis, E
    Zamboni, P
    Mascoli, F
    Regoli, D
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (02) : 141 - 149
  • [6] Urotensin-II receptor antagonists
    Carotenuto, A
    Griecio, P
    Rovero, P
    Novellino, E
    [J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (03) : 267 - 275
  • [7] Urotensin II: Evidence for cardiac, hepatic and renal production
    Charles, CJ
    Rademaker, MT
    Richards, AM
    Yandle, TG
    [J]. PEPTIDES, 2005, 26 (11) : 2211 - 2214
  • [8] The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats
    Clozel, M
    Hess, P
    Qiu, CB
    Ding, SS
    Rey, M
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (03) : 1115 - 1121
  • [9] Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt):: First demonstration of a pathophysiological role of the urotensin system
    Clozel, M
    Binkert, C
    Birker-Robaczewska, M
    Boukhadra, C
    Ding, SS
    Fischli, W
    Hess, P
    Mathys, B
    Morrison, K
    Müller, C
    Müller, C
    Nayler, O
    Qiu, CB
    Rey, M
    Scherz, MW
    Velker, J
    Weller, T
    Xi, JF
    Ziltener, P
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) : 204 - 212
  • [10] Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord
    Coulouarn, Y
    Lihrmann, I
    Jegou, S
    Anouar, Y
    Tostivint, H
    Beauvillain, JC
    Conlon, JM
    Bern, HA
    Vaudry, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15803 - 15808